中华老年多器官疾病杂志
中華老年多器官疾病雜誌
중화노년다기관질병잡지
CHINESE JOURNAL OF MULTIPLE ORGAN DISEASES IN THE ELDERLY
2014年
12期
922-925
,共4页
袁海成%许波%宋博%孙锋
袁海成%許波%宋博%孫鋒
원해성%허파%송박%손봉
脑梗死%细胞间黏附分子1%基质金属蛋白酶9%高压氧合作用%常压氧
腦梗死%細胞間黏附分子1%基質金屬蛋白酶9%高壓氧閤作用%常壓氧
뇌경사%세포간점부분자1%기질금속단백매9%고압양합작용%상압양
cerebral infarction%intercellular adhesion molecule-1%matrix metalloproteinase 9%hyperbaric oxygen%normobaric oxygen
目的：探讨常压氧（NBO）联合高压氧（HBO）对急性脑梗死血清细胞间黏附分子及基质金属蛋白酶-9（MMP-9）水平的影响。方法选择2011年12月至2014年3月在青岛市中心医院神经内科住院且发病24h内来院就诊的168例急性脑梗死患者为急性脑梗死组，将其随机分为常规治疗、HBO治疗及NBO联合HBO治疗3个亚组，分别在治疗前、治疗10d后采用酶联免疫吸附法（ELISA）测定各亚组血清可溶性细胞间黏附分子（sICAM-1）、可溶性E-选择素（sE-selectin，sES）及MMP-9水平，分析各亚组治疗前后神经功能缺损变化。另以50名正常人组成正常对照组。结果3个亚组治疗10d后，血清sICAM-1、sES和MMP-9水平分别较治疗前显著下降（t＝8.754～11.351，P＜0.01）；HBO亚组、NBO＋HBO亚组患者显著低于常规亚组（t＝2.237～4.162，P＜0.05或0.01）；与HBO亚组比较，NBO+HBO亚组患者血清sICAM-1、sES和MMP-9水平均显著下降（t＝2.141～2.366，P＜0.01）；HBO亚组、NBO＋HBO亚组治疗10d后，NIHSS评分较常规亚组显著下降（t＝5.367，P＜0.01；t＝9.943，P＜0.01），而NBO＋HBO亚组较HBO亚组治疗后NIHSS评分显著下降，差异具有统计学意义（t＝2.827，P＜0.01）。结论 NBO联合HBO治疗抑制血清sICAM-1、sES和MMP-9水平优于HBO亚组，且更能改善急性脑梗死患者临床预后。
目的：探討常壓氧（NBO）聯閤高壓氧（HBO）對急性腦梗死血清細胞間黏附分子及基質金屬蛋白酶-9（MMP-9）水平的影響。方法選擇2011年12月至2014年3月在青島市中心醫院神經內科住院且髮病24h內來院就診的168例急性腦梗死患者為急性腦梗死組，將其隨機分為常規治療、HBO治療及NBO聯閤HBO治療3箇亞組，分彆在治療前、治療10d後採用酶聯免疫吸附法（ELISA）測定各亞組血清可溶性細胞間黏附分子（sICAM-1）、可溶性E-選擇素（sE-selectin，sES）及MMP-9水平，分析各亞組治療前後神經功能缺損變化。另以50名正常人組成正常對照組。結果3箇亞組治療10d後，血清sICAM-1、sES和MMP-9水平分彆較治療前顯著下降（t＝8.754～11.351，P＜0.01）；HBO亞組、NBO＋HBO亞組患者顯著低于常規亞組（t＝2.237～4.162，P＜0.05或0.01）；與HBO亞組比較，NBO+HBO亞組患者血清sICAM-1、sES和MMP-9水平均顯著下降（t＝2.141～2.366，P＜0.01）；HBO亞組、NBO＋HBO亞組治療10d後，NIHSS評分較常規亞組顯著下降（t＝5.367，P＜0.01；t＝9.943，P＜0.01），而NBO＋HBO亞組較HBO亞組治療後NIHSS評分顯著下降，差異具有統計學意義（t＝2.827，P＜0.01）。結論 NBO聯閤HBO治療抑製血清sICAM-1、sES和MMP-9水平優于HBO亞組，且更能改善急性腦梗死患者臨床預後。
목적：탐토상압양（NBO）연합고압양（HBO）대급성뇌경사혈청세포간점부분자급기질금속단백매-9（MMP-9）수평적영향。방법선택2011년12월지2014년3월재청도시중심의원신경내과주원차발병24h내래원취진적168례급성뇌경사환자위급성뇌경사조，장기수궤분위상규치료、HBO치료급NBO연합HBO치료3개아조，분별재치료전、치료10d후채용매련면역흡부법（ELISA）측정각아조혈청가용성세포간점부분자（sICAM-1）、가용성E-선택소（sE-selectin，sES）급MMP-9수평，분석각아조치료전후신경공능결손변화。령이50명정상인조성정상대조조。결과3개아조치료10d후，혈청sICAM-1、sES화MMP-9수평분별교치료전현저하강（t＝8.754～11.351，P＜0.01）；HBO아조、NBO＋HBO아조환자현저저우상규아조（t＝2.237～4.162，P＜0.05혹0.01）；여HBO아조비교，NBO+HBO아조환자혈청sICAM-1、sES화MMP-9수평균현저하강（t＝2.141～2.366，P＜0.01）；HBO아조、NBO＋HBO아조치료10d후，NIHSS평분교상규아조현저하강（t＝5.367，P＜0.01；t＝9.943，P＜0.01），이NBO＋HBO아조교HBO아조치료후NIHSS평분현저하강，차이구유통계학의의（t＝2.827，P＜0.01）。결론 NBO연합HBO치료억제혈청sICAM-1、sES화MMP-9수평우우HBO아조，차경능개선급성뇌경사환자림상예후。
ObjectiveTo determine the effect of the combination of normobaric oxygen (NBO) and hyperbaric oxygen (HBO) on the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble E-selectin (sE-selectin, sES) and matrix metalloproteinase-9 (MMP-9) in the patients with acute cerebral infarction.Methods A total of 168 patients with acute cerebral infarction within 24 h after onset hospitalized in our department from December 2011 to March 2014 were enrolled in this study as acute cerebral ischemia group. They were prospectively and randomly divided into 3 subgroups, that is, routine treatment subgroup, HBO subgroup and NBO+HBO subgroups. Their serum levels of sICAM-1, sES and MMP-9 were measured by enzyme-linked immunosorbent assay (ELISA) before and at 10d after treatment. The National Institutes of Health Stroke Scale (NIHSS) was employed to assess their neurological defects. The other 50 practical health persons were enrolled as control group.Results After 10 days’ treatment, the serum levels of sICAM-1, sES and MMP-9 were significantly decreased in all 3 treatment groups. (t=8.754?11.351,P<0.01), with those of HBO and NBO+HBO subgroups obviously lower than the routine group (t=2.237?4.162,P<0.05 or 0.01). Compared with the HBO subgroup, these levels were more significantly decreased in the NBO+HBO subgroup (t=2.141?2.366,P<0.01). The HBO and NBO+HBO subgroups had markedly lower NIHSS scores than the routine subgroup at 10d after treatment (t=5.367,P<0.01;t=9.943, P<0.01), and the scores of the NBO+HBO subgroup were more significantly decreased than that of HBO subgroup (t=2.827,P<0.01).Conclusion The combined therapy of NBO+HBO is superior to HBO monotheray in the inhibition of serum sICAM-1, sES and MMP-9 levels, and improves the clinical prognosis of the patients with acute cerebral infarction.
